Anti-PAD4/PAD3 cross-reactive antibodies are important in the pathogenesis of RA in that they markedly increase the catalytic efficiency of PAD4 by decreasing its requirement for calcium to be active. This evidence concerns the gene PADI3 and rheumatoid arthritis.